Biocytogen Pharmaceuticals (beijing) Co., Ltd.

Biocytogen Jiangsu Co., Ltd.

Biocytogen Pharmaceuticals Co., Ltd.

Chaoshe Guo

Yang Bai

Yuelei Shen

Rui Huang

Yanan Guo

Jiawei Yao

Xiaofei Zhou

Meiling Zhang

Lei Zhao

Chengzhang Shang

The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) CD3e (T-cell surface glycoprotein CD3 epsilon chain), and methods of use thereof.

Genetically modified non-human animal with human or chimeric CD3e

The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) LAG3, and methods of use thereof.

Genetically modified non-human animal with human or chimeric LAG3

The present disclosure relates to the genetically modified non-human animals that express a human or chimeric OX40, and methods of use thereof.

Genetically modified non-human animal with human or chimeric OX40

The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) CD40, and methods of use thereof.

Genetically modified mice expressing humanized CD40

Provided are a humanized transgenic non-human animal, especially a rodent, in particular a transgenic mouse containing a human interleukin 17A (IL-17A) gene, a human gene 17RA (IL-17RA) and/or a human TNF-alpha gene, and a preparation method therefor and the use thereof.

Humanized transgenic animal

Non-human animals, methods and compositions for making and using the same, are provided, wherein the non-human animals comprise a humanized programmed death-ligand 1 (PD-L1, PDL1, or B7-H1). Such non-human animals may be described, in some embodiments, as having a genetic modification to an endogenous PD-L1 gene so that the non-human animals express a humanized PD-L1 protein that includes a human portion and an endogenous portion (e.g., a non-human portion).

Genetically modified non-human animal with human or chimeric PD-L1

The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) programmed cell death protein 1 (PD-1), and methods of use thereof. In one aspect, the animals have an insertion of a sequence encoding a human or humanized programmed cell death protein 1 (PD-1) at an endogenous PD-1 gene locus. This animal model can express a PD-1 protein containing a functional domain of the human PD-1 protein, and can be used as an animal model for developing therapeutics for human diseases and disorders, and assessing the toxicity and/or the efficacy of these human therapeutics.

Genetically modified non-human animal with human or chimeric PD-1

The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) IL15, and methods of use thereof.

Genetically modified non-human animal with human or chimeric IL15

The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) IL4R and/or IL4, and methods of use thereof.

Genetically modified non-human animal with human or chimeric genes

This disclosure relates to genetically modified animal expressing human or chimeric (e.g., humanized) programmed death-ligand 1 (PD-L1, PDL1, or B7-H1), and methods of use thereof. In one aspect, the disclosure relates to genetically-modified, non-human animals whose genome comprises at least one chromosome comprising a sequence encoding a human or chimeric programmed death-ligand 1 (PD-L1).

The present disclosure relates to the genetically modified non-human animals that express a human or chimeric (e.g., humanized) Lymphocyte Activation Gene 3 (LAG-3), and methods of use thereof.

Growing community of inventors

Beijing, China

Chaoshe Guo